The dominant signal is the near-exit of Wasatch Advisors, a significant active holder, which sold ~13.8M shares. Monitor for further institutional distribution in upcoming 13F filings and any insider buying to confirm a floor. The stock's low analyst bullishness (0% buy) and mixed cluster suggest continued downside risk absent a catalyst.
ESPR drugs
ESPR drug pipeline →How similar events traded
Executive Summary
Esperion Therapeutics (ESPR) saw a mixed institutional cluster in 2026-Q2: 6 buyers (net +$5.0M) led by JPMorgan doubling its stake, but 8 sellers (net -$48.4M) dominated by Wasatch Advisors exiting 87.8% of its position. The net selling pressure of ~$43.5M, concentrated in near-exit moves by large active managers, signals fading conviction despite modest accumulation by passive and smaller asset managers. The divergent insider activity (score 17/100, no open-market insider buying) weakens the buy-side signal.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$43.4M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| JPMorgan | DOUBLED | +103.7% | $4.4M | $2.6M |
| Citigroup | DOUBLED | +187.6% | $1.2M | $848.0K |
| Bank Of New York Mellon | ADD | +32% | $2.3M | $794.0K |
▼ Sellers (8)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Wasatch Advisors | NEAR_EXIT | -87.8% | $43.2M | -$37.1M |
| Nuveen | NEAR_EXIT | -84.1% | $9.9M | -$8.1M |
| Deutsche Bank | NEAR_EXIT | -75.6% | $3.0M | -$2.2M |
Key Facts
- 6 institutional buyers added $5.0M in new positions, led by JPMorgan doubling to $4.4M
- 8 institutional sellers reduced holdings by $48.4M, led by Wasatch Advisors near-exiting a $43.2M position
- Net institutional outflow of ~$43.5M, with 5 of 8 sellers executing near-exit moves
- No open-market insider buying (confluence score 17/100, divergent)
- Top holders BlackRock ($70M) and State Street ($23M) did not materially change positions in this cluster
Financial Impact
Net institutional selling of approximately $43.5M, with Wasatch Advisors alone reducing by $37.1M (86% of total selling)
Risk Factors
- Wasatch Advisors' near-exit could signal fundamental concerns not yet public
- Low analyst conviction (0% buy) and no insider buying suggest limited support
- Institutional selling may accelerate if no positive catalyst emerges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ESPR-2026-Q2 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 Viewing No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers